Bristol-Myers: raises targets for 2018

(CercleFinance.com) - Bristol-Myers Squibb has raised its adjusted EPS target range for 2018 to between 3.
35 dollars and 3.45 dollars, compared to 3.15 dollars to 3.30 dollars previously, with mid-single-digit sales growth.

Over the first three months of the year, the pharmaceutical group recorded EPS that was up 12% at 94 cents, ten cents above the consensus, on revenues that were up 5% to nearly 5.2 billion dollars.

“We delivered strong commercial performance with continued growth for our key franchises, Opdivo and Eliquis, and obtained FDA approval for Opdivo plus Yervoy in renal cell carcinoma,” said Giovanni Caforio, M.D., chairman and chief executive officer.


Copyright (c) 2018 CercleFinance.com. All rights reserved.